Quoin Pharmaceuticals Initiates Clinical Testing of QRX003 in Pediatric Netherton Syndrome Patient
• Quoin Pharmaceuticals has begun clinical testing of QRX003 in a young child with Netherton Syndrome at Children's Health Ireland, marking the first evaluation in a pediatric patient.
• The clinical assessment is led by Dr. Alan Irvine, a leading dermatologist, aiming to broaden the data set for QRX003 and potentially lower the eligibility age for treatment.
• QRX003 is currently in late-stage clinical trials with promising data showing improvement across multiple endpoints and no treatment-related adverse events in older patients.
• Quoin plans to expand the clinical assessment to include additional pediatric subjects in Spain and has opened or plans to open clinical sites in the US, Saudi Arabia, and the UK.
Quoin Pharmaceuticals Initiates Pediatric Trial of QRX003 for Netherton Syndrome
• Quoin Pharmaceuticals has begun clinical testing of QRX003 in a pediatric patient with Netherton Syndrome in Dublin.
• The company plans to expand the trial to include three additional pediatric patients in Spain.
• QRX003 is currently in late-stage clinical trials, showing promising results with no treatment-related adverse events.
• Quoin is expanding its clinical sites to include locations in Saudi Arabia and the United Kingdom.
© Copyright 2025. All Rights Reserved by MedPath